A career in neuroscience...
Phil’s career has been marked by groundbreaking work in neuroscience, spanning addiction, cognition enhancement, and psychosis research. He was instrumental in leading the development of CB1 antagonists for addiction and cognition enhancement, which influenced Alzheimer’s and schizophrenia research. His leadership extended to forming strategic collaborations, overseeing neuroscience portfolios, and playing a pivotal role in transitioning Pfizer’s neuroscience assets into the successful launch of Cerevel Therapeutics.
1985-1988: University of Nottingham
Completed a Bachelor of Pharmacy with Honors, focusing on foundational pharmaceutical sciences.
1997-2006: Pfizer (CNS Research)
Led innovative drug discovery projects, including a CB1 antagonist program that reached Phase 3 clinical trials.
1993-1997: Yale University (Postdoctoral Research)
Conducted groundbreaking research on receptor regulation, revealing stress-related mechanisms in neurobiology.
2007-2009: Executive Director, Best in Class Unit, Pfizer
Managed high-priority drug programs across schizophrenia, bipolar disorder, and Alzheimer’s, achieving significant preclinical milestones.
2009-2011: Executive Director, Neurodegeneration, Pfizer
Led teams focused on Alzheimer’s and Parkinson’s disease research, enhancing Pfizer’s CNS portfolio.
2006-2007: Director, Schizophrenia/Cognition Team, Pfizer
Directed research efforts targeting schizophrenia and cognitive disorders, driving portfolio advancements.
2013-2016: Executive Director, Business Research & Operations, Pfizer
Built operational support models for Pfizer's Neuroscience & Pain Research Unit, fostering external collaborations and acquisitions.
2017-2018: Vice President, Portfolio Technologies, Pfizer
Developed cross-functional technology platforms and strategies for neurodegeneration research within internal medicine.
2011-2013: Executive Director, Neuro Opportunities, Pfizer
Spearheaded external partnerships and collaborations to expand Pfizer’s neuroscience assets.
2016-2017: Vice President, Circuits, Neuro-Opportunities, Pfizer
Advanced screening technologies and neurobiology strategies, streamlining discovery pipelines.
2018-2024: Vice President, Biology, Cerevel Therapeutics
Led the emraclidine program to Phase 1b proof-of-concept, establishing Cerevel as a neuroscience leader.
2024-Present: Philip A. Iredale Consulting LLC
Launched a consultancy offering expertise in neurology, drug development, and portfolio strategy.
1989: UK Pharmacist Registration
Officially entered the Pharmaceutical Register, marking the start of his professional career.
1989-1992: University of Nottingham (PhD)
Earned a PhD in signal transduction pathways, pioneering methods to measure neurotransmitter release and intracellular calcium levels.
Philip A. Iredale Consulting
